All Stories

  1. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

    Article • American Journal of Hematology, June 2018, Wiley

    TAMAS DR MASSZI

  2. Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature

    Article • Journal of Oncology, January 2018, Hindawi Publishing Corporation

    Gabor Mikala, TAMAS DR MASSZI

  3. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

    Article • British Journal of Haematology, May 2017, Wiley

    TAMAS DR MASSZI

  4. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

    Article • British Journal of Haematology, February 2017, Wiley

    TAMAS DR MASSZI, Dr Albert Oriol

  5. Allogén vérképzőőssejt-átültetés Magyarországon

    Article • Orvosi Hetilap, February 2017, Akademiai Kiado

    TAMAS DR MASSZI